Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 04 May 2021 Primary endpoint (progression-free survival (PFS)) has been met, according to the results published in the Clinical Cancer Research.
  • 04 May 2021 Results (n=181; data cut off date: 14 Sept, 2018) of veliparib plus platinum chemotherapy followed by veliparib maintenance demonstrated improved PFS as first-line treatment for ED-SCLC, published in the Clinical Cancer Research.
  • 17 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top